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Oxidative stress is a hallmark of Alzheimer’s disease (AD). We propose that rather than causing damage
because of the action of free radicals, oxidative stress deranges signaling pathways leading to tau
hyperphosphorylation, a hallmark of the disease. Indeed, incubation of neurons in culture with 5 mM
beta-amyloid peptide (Aβ) causes an activation of p38 MAPK (p38) that leads to tau hyperpho-
sphorylation. Inhibition of p38 prevents Aβ-induced tau phosphorylation. Aβ-induced effects are
prevented when neurons are co-incubated with trolox (the water-soluble analog of vitamin E).
We have conﬁrmed these results in vivo, in APP/PS1 double transgenic mice of AD. We have found
that APP/PS1 transgenic mice exhibit a high level of P-p38 in the hippocampus but not in cortex and this
is prevented by feeding animals with a diet supplemented with vitamin E.
Our results underpin the role of oxidative stress in the altered cell signaling in AD pathology and
suggest that antioxidant prevention may be useful in AD therapeutics.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
The p38 MAPK is a 38 kD polypeptide with 4 isoforms (α, β, γ, δ)
all of which are activated by dual phosphorylation at Thr180 and
Tyr182 residues [1]. Activated p38 phosphorylates serine and threo-
nine residues in a great variety of substrates, mostly kinases and
transcription factors. In Alzheimer’s disease (AD), increased p38 MAPK
activity in human brains was observed more than a decade ago [2].
Post-mortem brains of AD patients revealed that phospho-p38 MAPK
immune reactivity occurs at a very early stage of the disease [3,4].
In AD, tau, which is a target of p38, turns into a hyperpho-
sphorylated state by the action of several kinases one of which is
p38 [5–7]. The link between p38, tau phosphorylation, oxidative
stress, and cell cycle-related events in Alzheimer’s was shown by
Zhu et al. [8]. Studies using transgenic mice exhibiting hyperpho-
sphorylated tau also show positive correlation between phos-
phorylated (activated) p38 and the level of aggregated tau [9].
We previously established that Aβ produces free radicals by
binding to heme which interferes with the respiratory chain and
subsequently increases peroxide production in mitochondria [10].
Thus, the aim of our work is to show if p38 links Aβ-induced
oxidative stress with tau hyperphosphorylation both in vitro
(primary neurons incubated with Aβ) and in vivo (an animal
model of AD, double transgenic for amyloid precursor protein/
presenilin1). We also checked the possible beneﬁcial effects of
vitamin E in the prevention of Aβ-associated damage. Vitamin E is
a powerful antioxidant but its beneﬁcial effects in AD are not clear.
Our results showed that P-p38 increases after Aβ treatment. We
also found that the increased tau hyperphosphorylation caused by
Aβ is dependent on p38 as it is prevented by speciﬁc inhibition of
this kinase. Finally, we showed that incubation with trolox (the
soluble vitamin E analog) prevents Aβ-induced p38 activation.
Furthermore, supplementation of mice chow with vitamin E for
21 days prevents p38 activation in APP/PS1 mice.
Materials and methods
Primary culture of cortical neurons
Primary cultures of rat cortical neurons were prepared from the
cerebral cortex of 14- or 15-day-old rat fetuses. Brieﬂy, the cerebral
cortex of fetuses obtained under sterile conditions was dissected
and dissociated mechanically, by pipetting 10 times with a 10 mL
pipette in DMEM (Gibco Invitrogen Corporation, Barcelona, Spain).
The cell suspension was ﬁltered through a nylon mesh with a pore
size of 90 μm. Cell suspensions were plated (5  104 cells/cm2) on
poly-L-lysine-coated dishes. After attachment of the cells (1 h), the
plating medium was changed to DMEM containing 10% FBS
supplemented with antibiotics (1%) and fungizone (1%). Cultures
were grown in a humidiﬁed atmosphere of 5% CO2/95% air at 37 1C
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for three days. Cells were then exposed to cytosine-β-D-arabino-
furanoside (5 μM) for 24 h to inhibit proliferation of non-neuronal
cells. The purity of neurons and possible contamination by astro-
cytes were assessed by immunoﬂuorescence using anti-GFAP and
anti-MAP-2 antibodies. Under our isolation conditions, 99% of the
cells were neurons.
Cell treatment
Four days after seeding, cells were treated with 5 mM soluble
Aβ(1-42). Brieﬂy, soluble Aβ(1-42) peptides were dissolved as fol-
lows: 1 mg of peptide was dissolved in 100 µl 1% NH4OH and
2100 µl of sterile PBS. (Gibco, Invitrogen Corporation, Barcelona,
Spain), and incubated for 24 h at 4 1C. Cells were also treated with
1 mM of Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-car-
boxylic acid), a water-soluble derivative of vitamin E (Sigma-
Aldrich, St. Louis, MO).
To study the effect of inhibiting p38 on tau phosphorylation,
cells were pre-incubated with 10 mM of SB203580 (Sigma-Aldrich,
St. Louis, MO) for 30 min prior to the addition of 5 mM of Aβ(1-42).
Animal model
Nine APPswe, PSEN1dE9-85Dbo/J transgenic mice and nine
wild type mice from the same colony aged nine months were
used for this study. Mice were maintained individually under a
12:12-h dark-light cycle at 23 7 1 1C and 60% relative humidity,
and were provided with a standard chow diet (PANLAB S.L.) and
water ad libitum. Control animals were fed a standard 2014 diet
(Harlan laboratories) and the treated group was fed the same diet
but enriched with 800 IU/kg of α-tocopheryl acetate. Both groups
ate the same amount of food (data not shown).
The animals were anesthetized with inhalatory anesthesia
(SEVOranes) and then sacriﬁced. Hippocampus and cortex were
isolated, freeze-clamped and stored at 80 1C. The tissues were
lysed in cold lysis buffer for Western blot determinations (Tris:
76.5 mM; pH: 6.8; SDS: 2%; Glicerol: 10%; supplemented with
2 mM sodium orthovanadate and proteases inhibitor [Sigma-
Aldrich]). Homogenates were sonicated on ice for 3 s and incu-
bated for 10 min at 4 1C. Protein concentration in the samples was
determined using the Lowry method.
All animal experimental procedures used in this study were
approved by the Committee on Ethics in Research of the Faculty of
Medicine, University of Valencia, Spain.
Western blotting analysis
Protein extracts from cultured neurons were mixed with equal
volumes of sodium dodecyl sulphate (SDS) buffer [0.125 M Tris–
HCl, pH 6.8, 2% SDS, 0.5% (v/v) 2-mercaptoethanol, 1% bromophe-
nol blue, and 19% glycerol] and then boiled for 5 min. Proteins
were separated by SDS- polyacrylamide gel electrophoresis gels
and transferred to nitrocellulose membranes which were incu-
bated overnight at 4 1C with appropriate primary antibodies: anti-
p38 (Cell Signaling), anti-p-p38 (Cell Signaling) and anti-p-tau 231
(Genscript). The protein levels of α-tubulin (Santa Cruz Biotech-
nology, Inc.) were used as a loading control. Thereafter, mem-
branes were incubated with a secondary antibody for 1 h at room
temperature. Speciﬁc proteins were visualized by using the
enhanced chemiluminescence procedure as speciﬁed by the man-
ufacturer (Amersham) and quantiﬁed by densitometry using a Bio-
Rad scanning densitometer (Bio-Rad, Hercules, CA, USA).
Statistics
Measurements from individual cultures were always per-
formed in triplicate. Results are expressed as mean 7 SD. Statis-
tical analysis was performed by the least-signiﬁcant difference
test, which consists of two steps: ﬁrst an analysis of variance was
performed. The null hypothesis was accepted for all numbers of
those sets in which F was non-signiﬁcant, at the level of p 4 0.05.
Second, the sets of data in which F was signiﬁcant were examined
by the modiﬁed t-test using p r 0.05 as the critical limit. We used
the Student T-test to compare two means in animal experiments
and T-test for paired samples in experiments in neurons in culture.
Our analysis of variance shows that samples did not follow a
normal distribution and thus, we used the Mann–Whitney test for
nonparametric samples.
Results
Vitamin E analogue, trolox, prevents p38 activation in Aβ treated neurons in primary
culture
Incubation of neurons in culture with Aβ induced an activation of p38 (Fig. 1).
This activation which was determined as the ratio between P-p38/total p38, was
prevented by co-incubation with trolox.
Vitamin E supplementation prevents the activation of p38 in AD mice
in vivo
To determine if our ﬁndings in cells in culture could be
conﬁrmed in vivo we used the double transgenic mice APP/PS1.
Fig. 1. Trolox prevents Aβ dependent p38 activation in neurons in primary culture.
Representative Western blots are shown. In all cases, values are means 7 SD of
9 experiments. Data were normalized with tubulin values. **p o 0.01 compared to
control values; þ þpo 0.01 compared to values obtained with Aβ.
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Fig. 2. Vitamin E supplementation prevents activation of p38 in AD mice in vivo.
Representative Western blots are shown. In all cases, values are means 7 SD of
9 mice (A) or 6 mice (B). Data were normalized with tubulin values, *p o 0.05
compared to values found in wild type mice (WT) or in mice fed with standard
diet (TG).
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Our results showed that the hippocampus of AD mice expressed
high levels of P-p38 compared to WT animals (Fig. 2A) and this
was prevented when animals were fed with a diet supplemented
with vitamin E (Fig. 2B). This increase did not occur in samples
from brain cortex (data not shown).
p38 activation leads to an increase in P-tau in neurons in primary
culture. Prevention by trolox
Using a speciﬁc inhibitor of p38 (SB203580), we conﬁrmed that
p38 activation, leads to tau hyperphosphorylation. Fig. 3 shows
that Aβ-induced tau hyperphosphorylation is p38 dependent as
incubation with SB203580 prevents it. When we cultured neurons
in the presence of Aβ we observed an increase in tau hyperpho-
sphorylation that was prevented by trolox (see Fig. 4). We have
also measured the effect of p38 inhibitor together with trolox and
while both independently protect from Aβ toxicity, their effects are
not additive, further suggesting that the protective effects of trolox
may be mediated by p38.
P-tau in the double transgenic murine model of AD
The content of P-tau in the hippocampus of ADmice is signiﬁcantly
higher than that of controls (see Fig. 5). This difference does not occur
in cortex (data not shown). Whenwe fed animals a diet supplemented
with vitamin E we did not ﬁnd a decrease in P-tau.
Discussion
Amyloid β toxicity and tau phosphorylation are related via oxidative
stress and p38 activation
Patients that have developed full-blown AD suffer from oxidative
stress. This has been shown in post-mortem brain samples. A
molecular response to oxidative stress is the phosphorylation, and
thus activation, of p38 [11]. To study the possible role of p38 in the
relationship between Aβ toxicity and tau phosphorylation, we used
fetal rat neurons in culture. We incubated them with Aβ and found a
signiﬁcant increase in p38 and tau phosphorylation. This activation
was prevented by co-incubation with trolox, the soluble vitamin E
analogue (see Fig. 1). To show that Aβ-induced tau phosphorylation
occurred due to the activity of p38, we inhibited it and observed a
prevention of tau phosphorylation induced by Aβ (Fig. 3).
In the previous years, the two major pathophysiological mechan-
isms associated with the development of AD, namely Aβ toxicity and
tau hyperphosphorylation were seen as independent factors [11].
Recent evidence, including some from our own laboratory, has shown
that this may not be the case. Indeed, it was previously shown that
glycogen synthase kinase 3 (GSK3β) can be activated by the presence
of Aβ and can itself phosphorylate tau. We further developed the
concept that Aβ and tau are mechanistically related and showed that
Aβ causes oxidative stress [12–14]. The group of Davies showed that
oxidative stress results in increased expression of an adaptive enzyme
formally called Adapt-78 and now known as RCAN1 which is an
inhibitor of calcineurin [15], the phosphatase that dephosphorylates
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Fig. 3. P38 activation leads to an increase in p-tau. Cultured neurons were pre-
incubated with a p38 inhibitor (SB203580) for 30 min. Prior to the treatment with 5 mM
of Aβ. Results showed that when p38 is inhibited there is a decrease in tau-
phosphorylation compared to neurons without p38 inhibitor. Representative Western
blots are shown. In all cases, values are means 7 SD of 4 experiments. **p o 0.01
compared to control values. þp o 0.05 compared to values obtained with Aβ.
0
0.5
1
1.5
2
2.5
3
P-
ta
u
tu
Control
P-tau
bulin
**
Ab Ab 
+
+ Trolox
Fig. 4. Effect of Aβ peptide and trolox in the expression of p-tau. Cultured neurons
treated with 5 mM of Aβ showed signiﬁcantly higher expression of p-tau (p o 0.05).
Trolox reverted the Aβ-induced effects. Representative Western blots are shown. In
all cases, values are means 7 SD of 9 experiments. **p o 0.05 compared to control
values. þp o 0.05 compared to values obtained with Aβ.
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Fig. 5. P-tau in AD mice model. P-tau was higher in the hippocampus of AD
transgenic mice compared to wild type mice. Representative Western blots are
shown. In all cases, values are means 7 SD of 9 experiments. *p o 0.05 compared
to WT animals.
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Tau. We described a role of the oxidative stress-induced upregulation
of RCAN1 in AD [16]. We now propose that Aβ causes an increase in
oxidative stress that leads to phosphorylation of p38 which is a kinase
that uses tau (in its T231 residue) as a substrate. Thus, Aβ toxicity can
be mechanistically linked to an increased phosphorylation of tau via
p38 as we show here.
We have shown that p38 is involved in linking Aβ and tau, not only
in neurons in culture but also in vivo using the double transgenic
model of AD (APP/PS1). This is a good model of AD which, for instance
shows Aβ plaques and also tau hyperphosphorylation. It is well-
known from clinical autopsies that the cellular damage that occurs in
AD is not uniform. Some structures like the hippocampus are very
heavily damaged whereas others, like the motor, somatic sensory, and
primary visual areas are spared [17]. When we measured activation of
p38, in hippocampal cells and cortex we found that it is activated in
hippocampal cells but not in other cortex areas and that this follows a
pattern very similar to that of tau phosphorylation. The similar
topology of activation of p38 and phosphorylation of tau is a further
indication that p38 may be very important in linking Aβ toxicity with
tau hyperphosphorylation.
The role of the antioxidant properties of vitamin E in the treatment of
Alzheimer’s disease
The work of Sano et al. [18] gave impetus to the idea of vitamin E
as the treatment of AD. Recently, the same group has reported that
vitamin E beneﬁts also patients with mild to moderate Alzheimer’s
disease by slowing functional decline [19]. However there are a
number of studies questioning the efﬁcacy of vitamin E treatment
[20,21]. We reported that the high variability of results on the effect of
vitamin E in Alzheimer’s is due to differences in the individual
response to its antioxidant properties [22]. Vitamin E does not act as
an antioxidant equally in all patients. Only in those in whom the
vitamin lowered the oxidation of blood glutathione and the peroxida-
tion of plasma lipids did vitamin E cause an improvement in
Alzheimer’s disease. We suggest that there are two sub-populations
who react differently to treatment with vitamin E: patients for whom
vitamin E does act as an antioxidant, react favorably to treatment,
especially in terms of preventing functional decline, but on the other
hand, other patients for whom vitamin E does not act as an
antioxidant, do not respond favorably to treatment with this vitamin.
The paradox of vitamin E is that it is efﬁcient for some patients, but not
for others [22].
Because of the critical importance of reactive oxygen species in
abnormal signaling in AD [10] we tested the effect of p38 signaling in
AD and the protection by the vitamin E analogue, trolox. Vitamin E
acts not only as an antioxidant but also as modulator of several cell
signaling pathways, in fact it can act as a modulator of gene
expression. Recently it has been shown a signiﬁcant increase in mRNA
levels of the scavenger receptor CD36 in aortae of cholesterol fed
rabbits and shown that vitamin E treatment attenuated increased
CD36 mRNA expression [23]. Furthermore, CD36 mediates the upre-
gulation of Aβ toxicity by lipid peroxidation products [24].
On the other hand vitamin E inhibits the activation of p38, but
this is mediated by a lowering of oxidative stress [25]. Our results
indicate that oxidative stress is therefore central in the pathophy-
siology of the disease because it links Aβ with tau by various
mechanisms, one of them shown in this paper (see schematic
summary in Fig. 6) and that seriously preventing it (and not just
giving antioxidant vitamins to all patients [22]) may be a good
therapeutic approach if applied in the early stages of the disease.
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